This biotechnology company's shares jumped by 75% in the last quarter and secured a fresh $9 million in funding.

Eversept Partners Expands Vera Therapeutics Investment

On February 17, 2026, Eversept Partners revealed a significant purchase of Vera Therapeutics (NASDAQ: VERA), acquiring 264,468 shares. This transaction, valued at approximately $9.39 million based on the average share price for the quarter, marks a notable increase in their stake.

Transaction Details

According to an SEC filing dated February 17, 2026, Eversept Partners boosted its holdings in Vera Therapeutics by 264,468 shares during the fourth quarter. The estimated value of this purchase is $9.39 million, calculated using the quarter’s average share price. By the end of the quarter, the fund’s total position in Vera Therapeutics had grown by $73.99 million, reflecting both new acquisitions and gains in share value.

Key Portfolio Highlights

• Major holdings following the latest filing:
  • NASDAQ: VERA — $155.58 million (8.7% of assets under management)
  • NYSE: GSK — $131.41 million (7.4% of assets under management)
  • NASDAQ: UTHR — $123.08 million (6.9% of assets under management)
  • NASDAQ: ABVX — $88.71 million (5.0% of assets under management)
  • NASDAQ: NTRA — $76.63 million (4.3% of assets under management)
• As of Monday, Vera Therapeutics shares traded at $39.97, representing a 43% increase over the past year—far outpacing the S&P 500’s 19% gain during the same period.

Vera Therapeutics at a Glance

Business Overview

• Vera Therapeutics is focused on developing advanced therapies for severe immune-related conditions. Its leading candidate, atacicept, is undergoing Phase IIb trials for immunoglobulin A nephropathy, while MAU868 is in Phase II for BK viremia infections.
• The company operates a biotechnology model centered on research, development, and commercialization of proprietary biologic drugs, aiming for regulatory approval and future revenue from product sales and licensing agreements.
• Vera primarily serves healthcare professionals and patients affected by autoimmune and virus-induced kidney disorders, with a strong emphasis on the U.S. market.

Headquartered in Brisbane, California, Vera Therapeutics is a clinical-stage biotech firm specializing in immunological disease solutions. The company leverages a robust pipeline of biologic candidates to address unmet needs in nephrology and infectious diseases, with a strategy focused on advancing innovative treatments through late-stage clinical trials to secure a competitive edge in the biopharma industry.

Implications for Investors

Vera’s flagship drug, atacicept, is being developed to treat immunoglobulin A nephropathy, a serious kidney disorder with limited available therapies. The drug has already shown promising results in Phase 3 trials and is currently under priority review by the FDA, with a decision anticipated in July 2026. If approved, atacicept could be launched in the U.S. soon after.

Financially, Vera Therapeutics is well-positioned for this milestone, ending 2025 with roughly $714 million in cash, equivalents, and marketable securities—resources management expects will support operations through potential FDA approval and product launch.

Investor enthusiasm is evident: Vera’s shares surged over 75% last quarter following a major capital raise of about $261 million, with shares priced at $42.50 each.

This investment aligns with Eversept’s broader portfolio, which includes stakes in biotech and pharmaceutical innovators like Ultragenyx, Abivax, and GSK, highlighting a commitment to transformative medical advances. For Vera, the upcoming FDA verdict could be pivotal, potentially transitioning the company from a promising biotech to a commercial drug manufacturer.

Is Vera Therapeutics a Buy Right Now?

Before considering an investment in Vera Therapeutics, it’s important to note:

The Motley Fool Stock Advisor team recently identified their top 10 stock picks for current investors—Vera Therapeutics was not among them. The selected stocks are projected to deliver substantial returns in the coming years.

For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would have grown to $514,000*. Similarly, Nvidia made the list on April 15, 2005, and a $1,000 investment then would now be worth $1,105,029*.

As of March 16, 2026, Stock Advisor boasts an average return of 930%, far exceeding the S&P 500’s 187%. Don’t miss the latest top 10 recommendations—available through Stock Advisor—and join a community of investors dedicated to individual success.

*Stock Advisor returns as of March 16, 2026.